Insights from transgenic mouse models of ERBB2-induced breast cancer

Josie Ursini-Siegel, Babette Schade, Robert Cardiff, William J. Muller

Research output: Contribution to journalReview article

164 Citations (Scopus)

Abstract

One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.

Original languageEnglish (US)
Pages (from-to)389-397
Number of pages9
JournalNature Reviews Cancer
Volume7
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Transgenic Mice
Breast Neoplasms
Receptor Protein-Tyrosine Kinases
Neoplasm Metastasis
Phenotype
Recurrence
Growth
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Insights from transgenic mouse models of ERBB2-induced breast cancer. / Ursini-Siegel, Josie; Schade, Babette; Cardiff, Robert; Muller, William J.

In: Nature Reviews Cancer, Vol. 7, No. 5, 01.05.2007, p. 389-397.

Research output: Contribution to journalReview article

Ursini-Siegel, Josie ; Schade, Babette ; Cardiff, Robert ; Muller, William J. / Insights from transgenic mouse models of ERBB2-induced breast cancer. In: Nature Reviews Cancer. 2007 ; Vol. 7, No. 5. pp. 389-397.
@article{4be2251228eb4e3a8ed58308a6200937,
title = "Insights from transgenic mouse models of ERBB2-induced breast cancer",
abstract = "One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.",
author = "Josie Ursini-Siegel and Babette Schade and Robert Cardiff and Muller, {William J.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1038/nrc2127",
language = "English (US)",
volume = "7",
pages = "389--397",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Insights from transgenic mouse models of ERBB2-induced breast cancer

AU - Ursini-Siegel, Josie

AU - Schade, Babette

AU - Cardiff, Robert

AU - Muller, William J.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.

AB - One-third of patients with breast cancer overexpress the ERBB2 receptor tyrosine kinase, which is associated not only with a more aggressive phenotype but also reduced responsiveness to hormonal therapies. Over the past two decades, many ERBB2 mouse models for breast cancer have conclusively shown that this receptor has a causal role in breast cancer development. These mouse models have also enabled the mechanisms controlling tumour growth, angiogenesis, metastasis, dormancy and recurrence in ERBB2-positive breast cancer to be elucidated. In addition, a mouse model has recently been described that accurately recapitulates many of the hallmarks associated with the early stages of the human disease.

UR - http://www.scopus.com/inward/record.url?scp=34247499539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247499539&partnerID=8YFLogxK

U2 - 10.1038/nrc2127

DO - 10.1038/nrc2127

M3 - Review article

C2 - 17446858

AN - SCOPUS:34247499539

VL - 7

SP - 389

EP - 397

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 5

ER -